A Report on Children with CEP290 Mutation, Vision Loss, and Developmental Delay

[LANGUAGE= "English"] Mutations in CEP290, which encodes a centrosomal protein, cause Joubert syndrome, retinal dystrophy, and several other manifestations. Retinal dystrophy related to CEP290 mutation (Leber’s congenital amaurosis type 10) presents with a severe visual impairment from bir...

Full description

Saved in:
Bibliographic Details
Published in:Beyoglu eye journal Vol. 8; no. 3; pp. 226 - 232
Main Authors: Sahli, Esra, Kiziltunc, Pinar Bingol, Idil, Aysun
Format: Journal Article
Language:English
Published: Istanbul Kare Publishing 2023
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[LANGUAGE= "English"] Mutations in CEP290, which encodes a centrosomal protein, cause Joubert syndrome, retinal dystrophy, and several other manifestations. Retinal dystrophy related to CEP290 mutation (Leber’s congenital amaurosis type 10) presents with a severe visual impairment from birth, wandering eye movements, and oculodigital reflex. Fundus examination may initially be normal, but varying degrees of retinal pigmentation can be detected over time. This report presents 4 children who were referred to the ophthalmology clinic with a lack of eye contact and the suspicion of low vision. The ophthalmological examination revealed very poor visual function, the vision slightly improved over time, and enophthalmos became evident. There was neuromotor retardation in their history and mutations in the CEP290 gene were revealed in the whole-exome analysis. Both pediatricians and ophthalmologists should be aware of the coincidence between severe vision loss and neuromotor retardation and should refer patients for genetic testing if they suspect it. Genetic diagnosis will enable pa-tients to be followed both neurologically and ophthalmologically and to benefit from rehabilitation opportunities that will contribute to visual and neurological development. It will also allow the family to receive genetic counseling on disease progression and heredity, and to follow ongoing gene therapy studies for mutations in the relevant gene.
ISSN:2459-1777
2587-0394
DOI:10.14744/bej.2023.37233